Literature DB >> 1818761

Solid state 31NMR studies of the conversion of amorphous tricalcium phosphate to apatitic tricalcium phosphate.

J E Roberts1, M Heughebaert, J C Heughebaert, L C Bonar, M J Glimcher, R G Griffin.   

Abstract

The hydrolytic conversion of a solid amorphous calcium phosphate of empirical formula Ca9 (PO4)6 to a poorly crystalline apatitic phase, under conditions where Ca2+ and PO4(3-) were conserved, was studied by means of solid-state magic-angle sample spinning 31P-NMR (nuclear magnetic resonance). Results showed a gradual decrease in hydrated amorphous calcium phosphate and the formation of two new PO4(3-)-containing components: an apatitic component similar to poorly crystalline hydroxyapatite and a protonated PO4(3-), probably HPO4(2-) in a dicalcium phosphate dihydrate (DCPD) brushite-like configuration. This latter component resembles the brushite-like HPO4(2-) component previously observed by 31P-NMR in apatitic calcium phosphates of biological origin. Results were consistent with previous studies by Heughebaert and Montel [18] of the kinetics of the conversion of amorphous calcium phosphate to hydroxyapatite under the same conditions.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1818761     DOI: 10.1007/BF02555846

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  11 in total

1.  Hydrogen-bonding in calcium-deficient hydroxyapatities.

Authors:  A S POSNER; J M STUTMAN; E R LIPPINCOTT
Journal:  Nature       Date:  1960-11-05       Impact factor: 49.962

Review 2.  Mineral chemistry and skeletal biology.

Authors:  J D Termine
Journal:  Clin Orthop Relat Res       Date:  1972       Impact factor: 4.176

3.  Comparative chemistry of amorphous and apatitic calcium phosphate preparations.

Authors:  J D Termine; E D Eanes
Journal:  Calcif Tissue Res       Date:  1972

4.  Hydrazine-deproteinated bone mineral. Physical and chemical properties.

Authors:  J D Termine; E D Eanes; D J Greenfield; M U Nylen; R A Harper
Journal:  Calcif Tissue Res       Date:  1973

5.  Intermediate states in the precipitation of hydroxyapatite.

Authors:  E D Eanes; I H Gillessen; A S Posner
Journal:  Nature       Date:  1965-10-23       Impact factor: 49.962

6.  Failure to detect an amorphous calcium-phosphate solid phase in bone mineral: a radial distribution function study.

Authors:  M D Grynpas; L C Bonar; M J Glimcher
Journal:  Calcif Tissue Int       Date:  1984-05       Impact factor: 4.333

7.  Conversion of amorphous tricalcium phosphate into apatitic tricalcium phosphate.

Authors:  J C Heughebaert; G Montel
Journal:  Calcif Tissue Int       Date:  1982       Impact factor: 4.333

8.  Solid-state phosphorus-31 nuclear magnetic resonance studies of synthetic solid phases of calcium phosphate: potential models of bone mineral.

Authors:  W P Aue; A H Roufosse; M J Glimcher; R G Griffin
Journal:  Biochemistry       Date:  1984-12-04       Impact factor: 3.162

9.  Investigation of the mineral phases of bone by solid-state phosphorus-31 magic angle sample spinning nuclear magnetic resonance.

Authors:  A H Roufosse; W P Aue; J E Roberts; M J Glimcher; R G Griffin
Journal:  Biochemistry       Date:  1984-12-04       Impact factor: 3.162

10.  Formation and structure of Ca-deficient hydroxyapatite.

Authors:  N C Blumenthal; F Betts; A S Posner
Journal:  Calcif Tissue Int       Date:  1981       Impact factor: 4.333

View more
  2 in total

1.  Solid-State P and H NMR Investigations of Amorphous and Crystalline Calcium Phosphates Grown Biomimetically From a Mesoporous Bioactive Glass.

Authors:  Renny Mathew; Philips N Gunawidjaja; Isabel Izquierdo-Barba; Kjell Jansson; Ana García; Daniel Arcos; María Vallet-Regí; Mattias Edén
Journal:  J Phys Chem C Nanomater Interfaces       Date:  2011-09-09       Impact factor: 4.126

2.  Contrasting In Vitro Apatite Growth from Bioactive Glass Surfaces with that of Spontaneous Precipitation.

Authors:  Yang Yu; Zoltán Bacsik; Mattias Edén
Journal:  Materials (Basel)       Date:  2018-09-12       Impact factor: 3.623

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.